# Tivic Health Systems, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Tivic Health Systems, Inc.). ## Overview Tivic Health Systems, Inc. is a U.S.-based therapeutics company built around two platforms: bioelectronic medical devices and TLR5-based immunotherapeutics. Its current commercial product is ClearUP, an FDA-cleared over-the-counter device for sinus pain, pressure, and congestion, while its development pipeline includes non-invasive vagus nerve stimulation and Entolimod for radiation injury and oncology-related indications. ## Products & services • ClearUP sinus pain, pressure and congestion device • Non-invasive vagus nerve stimulation (VNS) systems • Entolimod TLR5 agonist for acute radiation syndrome • Entolimod/Entolasta oncology and neutropenia programs • Accessories, shipping, and related ClearUP sales - **Consumer bioelectronic device** (100%) — ClearUP and related accessories sold for sinus pain, pressure, and congestion relief. - **Non-invasive vagus nerve stimulation** (0%) — Development-stage bioelectronic systems intended to modulate autonomic and neurologic pathways. - **TLR5 immunotherapeutics** (0%) — Drug candidates centered on Entolimod and related TLR5 agonist programs for radiation and oncology uses. - ClearUP sinus pain, pressure and congestion device - Non-invasive vagus nerve stimulation (VNS) systems - Entolimod TLR5 agonist for acute radiation syndrome - Entolimod/Entolasta oncology and neutropenia programs - Accessories, shipping, and related ClearUP sales ## Customers Tivic sells ClearUP to consumers directly online and through large retail and distribution channels, including resellers and marketplace partners. Its development-stage therapeutics are aimed at medical and government-related end markets such as acute radiation syndrome, neutropenia, and other oncology-related indications. - **Direct-to-consumer ClearUP users** (primary) — Individuals buying the FDA-cleared sinus relief device online for self-treatment of congestion and pressure. - **Reseller and distributor channels** (primary) — Medical supply and retail partners that stock ClearUP and sell it through their own channels. - **Clinical and institutional therapeutics buyers** (emerging) — Hospitals, clinical trial sites, and future specialty buyers for Entolimod and related programs. - **Government and radiation-injury end markets** (emerging) — Potential purchasers or users of Entolimod for acute radiation syndrome and related emergency indications. - Consumers seeking non-prescription sinus pain and congestion relief - Online shoppers buying directly through Tivic's website - Resellers and distributors such as medical supply channels - Retail marketplace customers reached through Amazon and big-box sites - Future clinical and institutional buyers for Entolimod-based therapies ## Geography Tivic is headquartered in the United States and its commercial activity is centered there through direct online sales and U.S. retail/distributor channels. Its development programs are also U.S.-based, with clinical and regulatory work tied to FDA pathways and domestic research partners. - Headquartered in the United States - ClearUP sold through U.S. online and retail channels - FDA-regulated development programs are centered in the U.S. - Clinical research partnerships support U.S.-based VNS work - Future therapeutics commercialization is expected to begin in the U.S. ## Strategy Tivic's strategy is to wind down the consumer ClearUP business and reallocate resources toward its biopharmaceutical and bioelectronic pipeline. Near term, the company is prioritizing Entolimod development, while also refining target indications for non-invasive vagus nerve stimulation through market and clinical research. - **Advance Entolimod development** (short-term) — The TLR5 program is the main long-term value driver and potential future revenue source. - **Exit or monetize ClearUP** (short-term) — The company is reducing reliance on consumer device sales to focus capital on therapeutics. - **Refine VNS indication strategy** (medium-term) — Targeting the most commercially attractive indications improves the odds of clinical and market success. - **Build a biopharmaceutical operating capability** (medium-term) — Drug development requires clinical, regulatory, and manufacturing capabilities beyond consumer devices. - Exit the consumer ClearUP business and reduce dependence on device sales - Advance Entolimod toward clinical development and eventual commercialization - Pursue neutropenia and oncology-related indications for TLR5 assets - Prioritize disease areas for non-invasive VNS using market and clinical data - Use third-party partners to keep the operating model lean - Build intellectual property and regulatory positioning around both platforms ## Risks Tivic faces execution risk from its transition away from consumer device sales toward clinical-stage therapeutics, where development timelines are long and outcomes uncertain. The company also depends on external funding, third-party service providers, and successful regulatory progress for both its TLR5 and VNS programs. - **Wind-down of the ClearUP business** [high] — Consumer sales currently generate the company's revenue, so exiting the business can sharply reduce top-line support. - **Clinical and regulatory failure in Entolimod** [high] — Drug candidates can fail in preclinical or clinical testing, and regulatory pathways may not lead to approval. - **Commercial adoption risk for VNS** [medium] — Non-invasive neuromodulation must prove clinical utility, payer acceptance, and market fit across target indications. - **Liquidity and financing dependence** [high] — The company has historically funded operations through securities issuance and continues to burn cash. - **Third-party supply chain and outsourcing dependence** [medium] — Manufacturing, clinical, and administrative functions rely heavily on external vendors and partners. - ClearUP wind-down may reduce near-term revenue and brand presence - Clinical development risk for Entolimod and VNS programs - Regulatory risk tied to FDA approvals, INDs, and trial outcomes - Funding risk because the company has a limited cash base and losses - Dependence on third-party manufacturers, CROs, and service providers ## Accounting The most important accounting judgments are inventory reserves, sales return reserves, stock-based compensation, and going-concern assessment. Because ClearUP revenue is tied to consumer sales and returns, and because the company is shifting its business mix, estimates around reserves and revenue timing can materially affect reported results. - **Inventory reserves** — Can affect cost of sales and gross profit - **Sales return reserves** — Affects reported net revenue - **Stock-based compensation** — Affects operating expenses and net loss - **Going concern** — Important for financial statement interpretation - Inventory reserves affect the carrying value of ClearUP stock - Sales return reserves affect net consumer-device revenue - Stock-based compensation can materially affect operating expenses - Going-concern judgments reflect funding and liquidity assumptions - Revenue is net of return reserves and includes accessories and shipping --- *Last updated: 2026-04-29T05:03:53.470372+00:00*